Price (90d)
$20.27Signal Score (90d)
60Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.14B | $134.28M | $0.49 |
| 2024 | $1.10B | $117.78M | $0.43 |
| 2023 | $1.09B | $145.63M | $0.55 |
| 2022 | $983.68M | $142.85M | $0.53 |
| 2021 | $843.92M | $134.32M | $0.53 |
Social Signal Score
Earnings
Thu, Nov 5(in 3 months)
Consensus estimate $0.17 per share
Typical surprise +9.1% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 4$0.16 vs $0.14beat
- Thu, May 7$0.13 vs $0.12beat
- Wed, Mar 4$0.21 vs $0.20beat
- Thu, Nov 6$0.16 vs $0.14beat
- Tue, Aug 5$0.12 vs $0.11beat
- Thu, May 8$0.11 vs $0.10beat
Estimates and results for STVN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
Project earnings forward and see what return today's price implies.
Seeded from STVN's reported EPS growth of -1.9% a year over 4 years.
- EPS in 5 years
- $0.45
- Implied price
- $15.64
- Return from $21.06
- -5.8% a year
To earn 15.0% a year on these assumptions you'd need to buy at $7.78 — -63.1% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 25 | 30 | 35 | 40 | 45 |
|---|---|---|---|---|---|
| -11.9% | -20.9% | -17.9% | -15.4% | -13.1% | -11.0% |
| -6.9% | -16.4% | -13.3% | -10.6% | -8.2% | -6.0% |
| -1.9% | -11.9% | -8.6% | -5.8% | -3.2% | -0.9% |
| 3.1% | -7.4% | -4.0% | -1.0% | 1.7% | 4.1% |
| 8.1% | -2.9% | 0.7% | 3.8% | 6.6% | 9.2% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Mentions (1)
- Newsmarketbeat.com·6d ago·Negative
Stevanato Group Q2 Earnings Call Highlights Stevanato Group NYSE: STVN reported second-quarter 2026 revenue growth of 8% as demand for higher-value drug containment and delivery products helped lift profitability, while the company updated its full-year outlook to reflect the divestiture of its California-based Balda C. Brewer subsidiary.
View source ↗